Table 1.
Patient Demographics, Baseline Clinical Characteristics, and Medications
| Characteristic | Value (N = 30 Patients) |
|---|---|
| Age, yr | 67 (7.4) |
| Sex, M, n (%) | 19 (63.3) |
| BMI, kg/m2 | 27.5 (4.7) |
| Smoking history, pack-years | 40.7 (26.5) |
| FEV1% predicted* | 65.0 (21.2) |
| FEV1/FVC ratio* | 0.53 (0.14) |
| Airflow obstruction, n (%) | |
| CB w/o airflow obstruction | 4 (13.3) |
| GOLD I | 4 (13.3) |
| GOLD II | 13 (43.3) |
| GOLD III | 9 (30.0) |
| TLC% predicted* | 111.6 (14.2) |
| RV% predicted* | 142.2 (39.8) |
| RV/TLC* | 48.7 (10.1) |
| Emphysema, % (−950 HU) | 8.0 (9.2) |
| 6MWT, m† | 443.2 (92.4) |
| CAT total score | 25.6 (7.1) |
| CAT phlegm score | 4.1 (0.8) |
| CAT cough score | 3.6 (0.9) |
| SGRQ total score | 59.6 (15.3) |
| SGRQ symptoms score | 76.1 (13.4) |
| Inhaled pharmacologic treatment, n (%) | |
| Short-acting only | 2 (6.7) |
| LABA/LAMA/ICS, LABA/LAMA, LABA only, LAMA only | 27 (90.0) |
| ICS only | 1 (3.3) |
| Oral roflumilast, n (%) | 3 (10) |
Definition of abbreviations: 6MWT = 6-minute-walk test; BMI = body mass index; CAT = Chronic Obstructive Pulmonary Disease Assessment Test; CB = chronic bronchitis; GOLD = Global Initiative for Chronic Obstructive Lung Disease; HU = Hounsfield units; ICS = inhaled corticosteroids; LABA = long-acting β-agonist bronchodilator; LAMA = long-acting muscarinic antagonist bronchodilator; RV = residual volume; SGRQ = St. George’s Respiratory Questionnaire; w/o = without.
Data are mean (SD) unless otherwise noted. Lung-function parameters are after bronchodilator treatment.
One patient did not have post-bronchodilator pulmonary-function testing done (protocol deviation).
Three patients did not perform the 6MWT.